Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients
Launched by RIO DE JANEIRO STATE UNIVERSITY · Jun 25, 2010
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
The main objective of this study is to evaluate whether magnesium supplementation is associated with improved blood pressure control and whether it has beneficial effects on the vascular structure and function in non-diabetic hypertensive patients who are receiving r diuretic therapy.
Patients will be evaluated in a prospective, randomized, double-blind study and will be admitted to the study if they reach all the inclusion criteria and no exclusion criteria.
In this study, magnesium chelate was chosen because of its better absorption rate. The dosages are different in many protocols but ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women aged between 40 and 65 years-old
- * Hypertension with mild blood pressure elevation:
- • Systolic BP between 140 and 159mmHg AND/OR
- • Diastolic BP between 90 and 99 mmHg
- • Antihypertensive monotherapy with daily use of thiazidic diuretic, at least in the last 30 days
- • Signature of the Informed Consent by the patient or his legal representative
- Exclusion Criteria:
- • Evidences for secondary hypertension
- • Hypertension in stage 2, SBP ≥ 160mmHg and/or DBP ≥ 100mmHg, before the beginning of supplementation
- • Blood pressure \> 180 x 100 mmHg in any phase of the study
- • Body mass index \> 35 kg/m2
- • Diabetes Mellitus
- • Renal disease presenting glomerular filtration rate \< 60ml/min
- • Coronary artery disease clinically evident with previous episode of myocardial infarction and/or myocardial revascularization
- • Clinical signs of heart failure
- • History of stroke
- • Any condition, disease or therapy that, under investigator's opinion, may influence objectives, results, or put in risk the safety of the patients.
- • Pregnancy
- • Patients should not be taking any mineral or vitamin supplements
- • Gastrointestinal conditions
About Rio De Janeiro State University
Rio de Janeiro State University (UERJ) is a prominent academic institution in Brazil, recognized for its commitment to advancing research and education across various disciplines, including health sciences. As a clinical trial sponsor, UERJ leverages its extensive resources and expertise to facilitate innovative research initiatives aimed at improving healthcare outcomes. With a focus on interdisciplinary collaboration, the university engages in cutting-edge studies that address critical health challenges, ensuring adherence to ethical standards and regulatory requirements. UERJ's dedication to fostering scientific inquiry and community health makes it a vital contributor to the landscape of clinical research in Brazil and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rio De Janeiro, Rj, Brazil
Patients applied
Trial Officials
Mario F Neves, MD, PhD
Principal Investigator
State University of Rio de Janeiro
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials